Eltrombopag

• Catalog No.: S2229
• CAS Number: 496775-61-2
• M. F.: C25H22N4O4
• M. W.: 442.46658
• Storage: -20°C

SYNONYMS

• IUPAC name: 3-(3-{2-[(4E)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2-hydroxyphenyl)benzoic acid
• IUPAC Traditional name: eltrombopag
• Synonyms: Promacta; Revolade; SB-497115-GR

DATABASE IDS

• CAS Number: 496775-61-2

PROPERTIES

• Target: TpoR
• Salt Data: Free Base
• Storage Condition: -20°C

DETAILS

Description (English)

Research Area: Cancer
Biological Activity:
Eltrombopag (SB-497115-GR, Promacta, Revolade) is a small molecule agonist of the c-mpl (TpoR) receptor with an IC50 of 0.69 μM for the inhibition of hERG K+ channel tail current. In preclinical studies, the compound was shown to interact selectively with the thrombopoeitin receptor, leading to activation of the JAK-STAT signaling pathway and increased proliferation and differentiation of megakaryocytes. Animal studies confirmed that administration could increase platelet counts.In addition, eltrombopag (SB-497115-GR, Promacta, Revolade) decreased proliferation of all cancer cell lines. [1][2]

REFERENCES

• Erickson-Miller CL et al. Leuk Res. 2010 Sep;34(9):1224-31.